A selective, irreversible inhibitor of BTK (IC₅₀ = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481; inhibits osteoclast function and reduces osteoclast-stimulated proliferation of multiple myeloma cells in animal models of…

AVL-292 is a Bruton’s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).